Advisor Group Inc. increased its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 0.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,941 shares of the life sciences company’s stock after buying an additional 13 shares during the period. Advisor Group Inc.’s holdings in Integra LifeSciences Holdings Corporation were worth $1,523,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eagle Asset Management Inc. boosted its holdings in shares of Integra LifeSciences Holdings Corporation by 39.0% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock valued at $89,778,000 after buying an additional 461,977 shares during the period. Koch Industries Inc. acquired a new position in shares of Integra LifeSciences Holdings Corporation in the 1st quarter valued at about $250,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Integra LifeSciences Holdings Corporation by 116.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 244,982 shares of the life sciences company’s stock valued at $10,322,000 after buying an additional 131,995 shares during the period. Strs Ohio boosted its holdings in shares of Integra LifeSciences Holdings Corporation by 60.4% in the 2nd quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock valued at $419,000 after buying an additional 2,900 shares during the period. Finally, Jennison Associates LLC boosted its holdings in shares of Integra LifeSciences Holdings Corporation by 12.3% in the 2nd quarter. Jennison Associates LLC now owns 697,772 shares of the life sciences company’s stock valued at $38,036,000 after buying an additional 76,548 shares during the period. 84.90% of the stock is owned by institutional investors and hedge funds.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 50.25 on Thursday. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The company has a market capitalization of $3.92 billion, a P/E ratio of 61.28 and a beta of 0.73. The firm’s 50 day moving average is $50.51 and its 200-day moving average is $48.58.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The business had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. During the same quarter in the prior year, the firm earned $0.40 EPS. The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. Equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/28/advisor-group-inc-boosts-stake-in-integra-lifesciences-holdings-corporation-iart.html.

In other news, Director Barbara B. Hill bought 5,050 shares of the stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average price of $49.33 per share, with a total value of $249,116.50. Following the acquisition, the director now owns 44,772 shares in the company, valued at $2,208,602.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Donald E. Morel, Jr. bought 2,500 shares of the stock in a transaction dated Thursday, August 3rd. The stock was purchased at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the acquisition, the director now owns 29,612 shares in the company, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 17,550 shares of company stock worth $864,842. 21.50% of the stock is owned by insiders.

IART has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Integra LifeSciences Holdings Corporation in a report on Monday, July 10th. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Raymond James Financial, Inc. lifted their price target on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Wednesday, July 26th. Finally, BidaskClub downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Five investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $53.64.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.